H.C. Wainwright reiterates Buy rating on ImmunityBio stock, citing promising lung cancer data

H.C. Wainwright reiterated its Buy rating and $8.00 price target for ImmunityBio Inc. (IBRX) following positive updated Phase 2 clinical data for ANKTIVA in advanced non-small cell lung cancer, which demonstrated significant lymphopenia reversal and improved survival benefits. This, coupled with promising early results from a chemotherapy-free glioblastoma pilot study, the launch of a Phase 2 trial for long COVID, and encouraging complete responses in a Phase I trial for Waldenstrom macroglobulinemia, underscores ANKTIVA's versatile immunorestorative potential across multiple challenging indications, supported by the company's strong liquidity.

Analysis

ImmunityBio (IBRX) received a reiterated Buy rating and an $8.00 price target from H.C. Wainwright, representing a significant premium to its current $2.57 price, following the presentation of compelling clinical data. The core driver is updated Phase 2 results for its lead asset, ANKTIVA, in advanced non-small cell lung cancer, which demonstrated a meaningful survival benefit; patients achieving an absolute lymphocyte count (ALC) over 1,200 cells/µL had a median survival of 15.8 months versus 11.5 months for those who did not. The drug's potential as a versatile immunorestorative therapy is further supported by promising, albeit very early-stage, data across other difficult-to-treat indications, including 100% disease control in a five-patient glioblastoma pilot study and complete responses in the first two patients of a Waldenstrom macroglobulinemia trial. The company's expansion into non-oncology areas, such as a new Phase 2 trial for long COVID, underscores this platform potential. Financially, ImmunityBio appears well-positioned to fund these programs, evidenced by a strong current ratio of 4.11. From a market perspective, the stock has shown recent positive momentum with an 8.44% return over the last week and offers a low correlation to the broader market, indicated by a beta of -0.07.

Key Decisions for Investors

• Given the positive clinical data across multiple indications and a significant gap between the current stock price and analyst targets, investors may consider the stock's bullish case centered on ANKTIVA's platform potential.
• It is crucial to weigh the promising results against the inherent risks of a clinical-stage biotech, as the highly positive data in glioblastoma and Waldenstrom macroglobulinemia are from very small patient cohorts.
• Investors should monitor upcoming clinical trial catalysts, as progress in the lung cancer, glioblastoma, and long COVID studies will be the primary determinants of future value creation.
• The stock's low beta of -0.07 suggests it may act as a portfolio diversifier, with its performance likely driven by company-specific catalysts rather than broader market movements.